Page History

...

1. Apply General rules for generating descriptions for templates
2. Exceptions:Concepts with product strength that is "not equal to" (e.g. with product strength expressed as a range, greater than, or less than) will have definition status 900000000000074008| Primitive (core metadata concept) and will have the appropriate Medicinal Product Form-only (MPF-only) concept as a stated parent.
3. For multiple ingredients, the ingredients in each description need to be in alphabetical order e.g. Codeine and paracetamol for FSN but Acetaminophen and codeine (for US PT).

   If BOSS differs from precise active ingredient BoSS <> Precise active ingredient:

   FSN Product containing precisely [substance](as[substance]) [number][SI unit of mass]/[1] each [dose form] (clinical drug) e.g Product containing precisely doxazosin (as doxazosin mesilate) 8 milligram/1 each prolonged-release oral tablet (clinical drug)

   PT [substance] (as[substance]) [SI unit of mass PT] [dose form] e.g. US with GB language Acceptability:

    Doxazosin (as doxazosin mesylate) 8 mg prolonged-release oral tabletPreferredDoxazosin (as doxazosin mesilate) 8 mg prolonged-release oral tabletAcceptable
4. Use of 'actuation' - 
   Product containing precisely budesonide 200 microgram/actuation conventional release powder for inhalation (clinical drug)
Use of 'vial powder':•Product containing precisely aztreonam 500 milligram/1 vial powder for conventional release solution for injection (clinical drug)JIRA ticket for implementation:

5.